Multiple myeloma is a heterogeneous condition characterized by the proliferation of monoclonal B-cells, for which there is currently no curative treatment available. Relapses are, unfortunately, common after first-line treatment. While the prognosis for relapsed refractory multiple myeloma is generally poor, advances in the treatment of relapsed or refractory multiple myeloma offer hope. However, the expansion of effective options in targeted treatment offers renewed optimism and hope that patients who fail on older therapies may respond to newer modalities, which are often used in combination. We review currently approved and novel investigational agents classified by mechanisms of action, efficacy, approved setting, and adverse events. We delve into future directions of treatment for relapsed/refractory multiple myeloma, reviewing novel agents and therapeutic targets for the future.
多发性骨髓瘤是一种以单克隆B细胞增殖为特征的异质性疾病，目前尚无根治性疗法。一线治疗后复发的情况较为常见。尽管复发难治性多发性骨髓瘤的预后普遍不佳，但该领域治疗进展为患者带来了希望。靶向治疗方案的拓展为传统疗法无效的患者提供了新的治疗可能，这些新型疗法常采用联合用药模式。本文根据作用机制、疗效、获批适应症及不良反应，系统综述了目前已获批及处于研究阶段的新型治疗药物。同时深入探讨了复发/难治性多发性骨髓瘤的未来治疗方向，并对新型药物及潜在治疗靶点进行展望。
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
肿瘤(癌症)患者之家